Form 4: Amgen Director Omar Ishrak Reports Acquisition of Common Stock

Director Omar Ishrak reports acquiring Amgen common stock through vested Restricted Stock Units (RSUs) and dividend equivalents.

Summary

• On May 6, 2025, Omar Ishrak, a director of Amgen Inc., acquired 129.4187 shares of Amgen common stock.
• The acquisition was through the vesting of Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program.
• The vested RSUs are paid in shares of Amgen's common stock on a one-to-one basis.
• The reported holdings include 255 Dividend Equivalents (DEs) granted pursuant to the Director Program.
• Following the transaction, Ishrak beneficially owns 5,275.4994 shares of Amgen common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a director, which is neither particularly positive nor negative.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but it outlines the ongoing vesting and payment of RSUs and dividend equivalents under the Director Incentive Program.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies like Amgen. Such filings provide transparency to investors regarding the actions of company insiders.

Comparison to Industry Standards

• Director compensation packages often include stock options, restricted stock units, and dividend equivalents to align the interests of directors with those of shareholders.
• The Amgen Inc. 2009 Director Incentive Program is similar to those offered by other large pharmaceutical companies such as Pfizer, Johnson & Johnson, and Merck, which also use equity-based compensation to incentivize their board members.
• The immediate vesting of RSUs is less common than graded vesting schedules, but it is not unusual for director compensation plans.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals director confidence.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Amgen, Director, Omar Ishrak, Common Stock, RSUs, Dividend Equivalents, Beneficial Ownership, Form 4, SEC Filing